Where does Eikon Therapeutics, Inc. 's balance sheet data come from?

Every line is extracted from Eikon Therapeutics, Inc. 's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Eikon Therapeutics, Inc. EIKN Balance Sheet Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY QoQ

Simplified Detailed

	Q1 '26	Q4 '25	Q1 '25
Cash and cash equivalents	$161.15M-21.2%	$104.9M—	$204.58M—
Short-term investments	$351.03M—	$231.07M—	——
Restricted cash	$400K—	$400K—	——
Prepaid expenses and other current assets	$16.92M—	$12.54M—	——
Total current assets	$529.5M—	$348.92M—	——
Property and equipment, net	$138.07M—	$142.9M—	——
Total assets	$850.83M—	$594.73M—	——
Accounts payable	$6.01M+164%	$681K—	$2.28M—
Operating lease liabilities, current	$9.74M—	$10.03M—	——
Total current liabilities	$45.06M—	$55.01M—	——
Operating lease liabilities, non-current	$245.09M—	$247.29M—	——
Finance Lease Liabilities (Total)	$0—	$0—	——
Operating Lease Liabilities (Total)	$254.83M—	——	——
Finance lease liabilities	$0—	$0—	——
Other non-current liabilities	$10M—	$10M—	——
Total liabilities	$300.16M—	$312.3M—	——
Retained earnings	-$1B—	-$920.51M—	——
Total stockholders' equity	$550.67M+186%	-$879.03M-53.7%	-$640.14M—
Total liabilities and stockholders' equity	$850.83M—	$594.73M—	——
Short- term Investments	$351.03M—	$231.07M—	——
Deferred Tax Assets and Other Non-Current Assets	$556K—	$4.18M—	——
Net Investment in Lease	$91.07M—	$90.97M—	——
Operating lease right-of-use assets	$91.07M—	$90.97M—	——
Other non-current assets	$556K—	$4.18M—	——
Operating Lease Right-of-Use Assets in Other Assets	$91.07M—	$90.97M—	——
Software and Technology Licenses, Net	$556K—	$4.18M—	——
Accounts Payable and Accrued Liabilities, Current	$29.32M—	$44.3M—	——
Total debt	$254.83M—	$257.32M—	——
Additional paid-in capital	$1.55B—	$41.48M—	——
Common stock; $0.001 par value; 6,000 shares authorized; 3,755 and 3,751 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively	$5K—	——	——
Preferred stock; $0.001 par value; 100 shares authorized; no shares issued and outstanding	$0—	$0—	——
Series A cumulative convertible preferred units (“preferred units”) (45,412 units outstanding at December 31, 2025 and 50,687 units outstanding at December 31, 2024	$0—	$1.16B—	——

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Where does Eikon Therapeutics, Inc. 's balance sheet data come from?: Every line is extracted from Eikon Therapeutics, Inc. 's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.